Business Context and Reporting Period
Company: Cryomedical Sciences, Inc. (Note: Metadata listed "Biolife Solutions Inc," but the filing text identifies the registrant as Cryomedical Sciences, Inc.)
Reporting Period: Quarterly Report (Form 10-Q) for the period ended December 31, 1995.
Business Overview: The Company researches, develops, manufactures, and markets products for hypothermic medicine, primarily the CMS AccuProbe(R) cryosurgical system used in urology, general surgery, and other fields.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 1995 | Six Months Ended Dec 31, 1994 |
|---|---|---|
| Revenue | $3,682,150 | $7,896,370 |
| Gross Profit | $2,042,474 | $4,076,173 |
| Gross Margin | 55% | 52% |
| Net Loss | $(1,003,497) | $(772,777) |
| Net Loss Per Share | $(0.04) | $(0.03) |
| Cash & Equivalents (End of Period) | $728,040 | $2,194,519 |
| Working Capital | $2,671,741 | $3,775,893 (as of June 30, 1995) |
| Total Liabilities | $3,045,250 | $4,420,978 (as of June 30, 1995) |
Cash Flow: Net cash used in operating activities was $414,787 for the six months ended December 31, 1995, compared to $608,078 in the prior year. Net cash used in investing activities was $38,342. Net cash provided by financing activities was $63,786.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 53% year-over-year for the six-month period, driven by a drop in AccuProbe system sales (9 units sold vs. 24 units in the prior year). The decline is attributed to a lack of formal Medicare reimbursement for urologic cryosurgery and uncertainty regarding insurance coverage.
- Expense Reductions: Operating expenses decreased significantly due to cost-cutting measures:
- Research and Development: Decreased 56% to $705,905.
- Sales and Marketing: Decreased 30% to $1,266,436.
- General and Administrative: Decreased 26% to $1,077,910.
- Worsening Net Loss: Despite expense reductions, the net loss increased to $1,003,497 from $772,777 in the prior year due to the substantial revenue drop.
- Liquidity: Cash and cash equivalents decreased by approximately $389,000 during the six-month period.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects current cash and working capital to fund operations for the next 12 months, contingent on sales levels. The Company anticipates substantial expenditures for R&D, manufacturing, and marketing in fiscal 1996.
- Subsequent Financing: On January 17, 1996, the Company received $1,910,000 in net proceeds from a convertible preferred stock sale to foreign investors to fund working capital and the AccuProbe 500 series launch.
- Key Risks:
- Reimbursement: Lack of uniform national insurance reimbursement guidelines (specifically Medicare) for urological cryosurgery is the primary factor limiting sales growth.
- Liquidity: The Company has no other major sources of liquidity besides product sales and may need to pursue short-term financing.
- Contingencies:
- Class Action Settlement: A stockholder class action suit was settled for $100,000 cash and $350,000 in stock. The settlement is pending court approval (hearing scheduled for February 15, 1996). The full $450,000 cost was accrued as of June 30, 1995.
- Employment Litigation: A former employee filed a gender bias and discrimination suit in October 1995; the case is in early discovery.
Investor Verification Checklist
- Verify the status of the $450,000 class action settlement pending court approval in February 1996.
- Monitor developments regarding Medicare and private insurer reimbursement policies for urological cryosurgery, as this is the primary driver of revenue volatility.
- Confirm the utilization of the $1.91 million proceeds from the January 1996 convertible preferred stock sale.
- Assess the impact of the gender bias litigation on future legal expenses and potential liabilities.
- Review the Company's ability to meet its budgeted $485,000 capital expenditure plan for fiscal 1996 given current cash burn rates.